Concepedia

Madeleine Willkom

MW

Statistics

Publications

9

Citations

526

H-Index

9

Active since

2002

Affiliations

Gilead Sciences (United States)(Current)

Madeleine Willkom is an author at Gilead Sciences (United States) specializing in antiviral therapy, life sciences, and antiviral agents.

Publications per year

2002–2022

9

Publications

9

The Th2 Lymphocyte Products IL-4 and IL-13 Rapidly Induce Airway Hyperresponsiveness Through Direct Effects on Resident Airway Cells

Rajeev Venkayya, Maggie Lam, Madeleine Willkom et al. · American Journal of Respiratory Cell and Molecular Biology · 2002 · 223 citations

, , +16

Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors

Gabriel Birkuš, Rujuta A. Bam, Madeleine Willkom et al. · Antimicrobial Agents and Chemotherapy · 2015 · 71 citations · Full text

, , +17

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I

Kristen Andreatta, Madeleine Willkom, Ross Martin et al. · Journal of Antimicrobial Chemotherapy · 2019 · 62 citations · Full text

, , +17

Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks

Rima Acosta, Madeleine Willkom, Ross Martin et al. · Antimicrobial Agents and Chemotherapy · 2019 · 60 citations · Full text

, , +17

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance

Rima Acosta, Madeleine Willkom, Kristen Andreatta et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2020 · 35 citations

, , +17

1–5 of 9